106261-48-7, As the paragraph descriping shows that 106261-48-7 is playing an increasingly important role.
With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.106261-48-7,4-((4-Methylpiperazin-1-yl)methyl)benzoic acid,as a common compound, the synthetic route is as follows.
Intermediate 42: W-(5-bromo-2-cyano-4-pyrimidinyl)-4-[(4-methyl-1 -piperazinyl) methyl]-W-(2-methylpropyl)benzohydrazide trifluoroacetate. Preparation of 4-[(4-methyl-1-piperazinyl)methyl]benzoyl chloride.Intermediate 38 (500 mg, 2.13 mmol) was dissolved in thionyl chloride (5 ml). The reaction mixture was refluxed for 6 hours. The solvent was evaporated in vacuo and the crude product was used without any further purification.To a stirred solution of Intermediate 41 (200 mg, 0.74 mmol) in pyridine (10 ml_), a mixture of the previously prepared acid chloride (539 mg, 2.13 mmol) and DIPEA (0.26 ml_, 1.48 mmol) in dry THF (10 ml.) was added and the resulting reaction mixture was stirred at room temperature for 2 hours. The solvent was evaporated in vacuo and the crude reaction mixture was purified by flash chromatography (silica gel, dichloromethane:methanol). The solid was repurified by HPLC (H2O, 0.1%TFA:ACN) to give the title compound. 1H NMR (300 MHz, DMSO) delta ppm: 11.36 (s, 1 H), 8.64 (s, 1 H), 7.92 (d, 2H), 7.48 (d, 2H), 3.98 (m, 1 H), 3.73 (s 2H), 3.38 (m, 4H), 3.02 (m 4H), 2.78 (s, 3H) 2.42 (m, 1 H), 2.05 (m, 1 H), 0.94 (d, 6H). [ES+ MS] m/z 486 (M)+.
106261-48-7, As the paragraph descriping shows that 106261-48-7 is playing an increasingly important role.
Reference：
Patent; GLAXO GROUP LIMITED; WO2008/107368; (2008); A1;,
Piperazine – Wikipedia
Piperazines – an overview | ScienceDirect Topics